KCS
MCID: KRT001
MIFTS: 50

Keratoconjunctivitis Sicca (KCS)

Categories: Eye diseases, Rare diseases

Aliases & Classifications for Keratoconjunctivitis Sicca

MalaCards integrated aliases for Keratoconjunctivitis Sicca:

Name: Keratoconjunctivitis Sicca 12 74 52 29 54 43 15 17 71
Keratitis Sicca 52 71
Xerophthalmia 52 71
Dry Eye Syndromes 71
Dry Eye Syndrome 52
Kcs 12

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases


External Ids:

Disease Ontology 12 DOID:12895
MeSH 43 D007638
SNOMED-CT 67 78946008
UMLS 71 C0013238 C0022575 C0043349 more

Summaries for Keratoconjunctivitis Sicca

MalaCards based summary : Keratoconjunctivitis Sicca, also known as keratitis sicca, is related to aplasia of lacrimal and salivary glands and sjogren syndrome, and has symptoms including eye manifestations, dryness of eye and dacryops. An important gene associated with Keratoconjunctivitis Sicca is LTF (Lactotransferrin), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Pseudoephedrine and Ephedrine have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and testes, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia : 74 Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry... more...

Related Diseases for Keratoconjunctivitis Sicca

Diseases related to Keratoconjunctivitis Sicca via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 491)
# Related Disease Score Top Affiliating Genes
1 aplasia of lacrimal and salivary glands 33.1 LTF HSPG2 AQP5
2 sjogren syndrome 32.8 TRIM21 SSB RO60 LTF HSPG2 CD79A
3 keratoconjunctivitis 31.9 TRIM21 NGF MUC5AC IL4 ALB
4 dry eye syndrome 31.7 TRIM21 SSB NGF MUC5AC LTF CCR6
5 keratitis, hereditary 31.1 NGF CD4 CCR6
6 proteasome-associated autoinflammatory syndrome 1 30.8 IL4 IL1A ALB
7 chronic graft versus host disease 30.7 IL1A CD79A CD4 ALB
8 dental caries 30.5 LTF CD79A ALB
9 autoimmune disease 30.4 TRIM21 RO60 IL4 IL1A CD79A CCR6
10 corneal disease 30.4 NGF IL1A CD4 CCR6 ALB
11 ocular cicatricial pemphigoid 30.4 NGF IL4 CD79A
12 cicatricial pemphigoid 30.4 NGF IL4 CD79A
13 bacterial infectious disease 30.3 LTF IL1A CD4 CCR6
14 chickenpox 30.3 IL4 CD4 CCR6 ALB
15 leprosy 3 30.3 IL4 CD4 CCR6 ALB
16 acquired immunodeficiency syndrome 30.2 CD79A CD4 CCR6 ALB
17 dacryoadenitis 30.1 HSPG2 CD4 CCR6 BPIFA2 AQP5
18 otitis media 30.1 MUC5AC IL4 CD79A ALB
19 peripheral nervous system disease 30.1 NGF IL4 CD4 CCR6 ALB
20 dysentery 30.1 IL1A CD4 CCR6 ALB
21 eye disease 30.0 NGF MUC5AC IL4 IL1A CD4 CCR6
22 demyelinating disease 30.0 NGF IL4 CD4 CCR6
23 blepharitis 30.0 MUC5AC LTF IL4 CD4 CCR6
24 chronic conjunctivitis 29.9 MUC5AC IL4 CD4 CCR6
25 crohn's disease 29.9 IL4 CD4 CCR6 ALB
26 celiac disease 1 29.8 IL4 CD79A CD4 CCR6 ALB
27 connective tissue disease 29.8 SSB IL4 IL1A HSPG2 CD4 CCR6
28 pulmonary fibrosis, idiopathic 29.8 IL4 IL1A CD4 CCR6 ALB
29 skin disease 29.8 IL4 IL1A CD79A CD4 CCR6 ALB
30 severe cutaneous adverse reaction 29.7 MUC5AC HSPG2 CD4 ALB
31 eyelid disease 29.7 MUC5AC CD4 CCR6
32 systemic scleroderma 29.7 TRIM21 SSB RO60 IL4 CD4 CCR6
33 xerophthalmia 29.7 TRIM21 SSB RO60 HSPG2 CD4 BPIFA2
34 cystic fibrosis 29.7 MUC5AC LTF HSPG2 CD4 ALB
35 myeloma, multiple 29.6 IL4 ERBB2 CD79A CD4 CCR6 ALB
36 conjunctival disease 29.5 MUC5AC IL4 CD4 CCR6 ALB
37 sialadenitis 29.2 TRIM21 SSB RO60 HSPG2 CD4 CCR6
38 collagen disease 29.2 TRIM21 SSB RO60 IL4 HSPG2 CD4
39 dermatitis, atopic 29.1 NGF MUC5AC IL4 IL1A CD4 CCR6
40 systemic lupus erythematosus 28.5 TRIM21 SSB RO60 LTF IL4 CD79A
41 myelopathy, htlv-1-associated 11.8
42 tropical spastic paraparesis 11.8
43 kenny-caffey syndrome, type 1 11.7
44 retrovirus-associated myelopathy 11.5
45 kenny-caffey syndrome 11.4
46 kenny-caffey syndrome, type 2 11.2
47 keratoconus posticus circumscriptus 11.2
48 premature ovarian failure 1 11.1
49 night blindness 10.7
50 conjunctivitis 10.6

Graphical network of the top 20 diseases related to Keratoconjunctivitis Sicca:



Diseases related to Keratoconjunctivitis Sicca

Symptoms & Phenotypes for Keratoconjunctivitis Sicca

UMLS symptoms related to Keratoconjunctivitis Sicca:


eye manifestations, dryness of eye, dacryops

MGI Mouse Phenotypes related to Keratoconjunctivitis Sicca:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 ALB AQP5 CCR6 CD4 CD79A ERBB2
2 immune system MP:0005387 10.1 ALB CCR6 CD4 CD79A ERBB3 HSPG2
3 digestive/alimentary MP:0005381 10.02 ALB AQP5 CD4 ERBB2 ERBB3 HSPG2
4 integument MP:0010771 9.85 CD4 ERBB2 ERBB3 FAM83H HSPG2 IL1A
5 mortality/aging MP:0010768 9.77 ALB AQP5 CD4 CD79A ERBB2 ERBB3
6 normal MP:0002873 9.28 ALB CCR6 CD4 CD79A ERBB2 ERBB3

Drugs & Therapeutics for Keratoconjunctivitis Sicca

Drugs for Keratoconjunctivitis Sicca (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 257)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pseudoephedrine Approved Phase 4 90-82-4 7028
2
Ephedrine Approved Phase 4 299-42-3 9294
3
Povidone Approved Phase 4 9003-39-8
4
Dimenhydrinate Approved Phase 4 523-87-5 441281
5
Glycerol Approved, Investigational Phase 4 56-81-5 753
6
Dipivefrin Approved Phase 4 52365-63-6 3105
7
Zinc Approved, Investigational Phase 4 7440-66-6 32051
8
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
9
Ethanol Approved Phase 4 64-17-5 702
10
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
11
Ofloxacin Approved Phase 4 82419-36-1 4583
12
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
13
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
14
Menthol Approved Phase 4 2216-51-5 16666
15
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
16
Sorbitol Approved Phase 4 50-70-4 5780
17
Pilocarpine Approved, Investigational Phase 4 92-13-7, 54-71-7 5910
18
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
19
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
20
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
21
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
22
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
23
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
24
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
25
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
26 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
27
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
28
Azithromycin Approved Phase 4 83905-01-5 55185 447043
29
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4
30
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
31 Rebamipide Investigational Phase 4 90098-04-7
32
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
33 Vasoconstrictor Agents Phase 4
34 Nasal Decongestants Phase 4
35 Anti-Ulcer Agents Phase 4
36 Antacids Phase 4
37 Cathartics Phase 4
38 Laxatives Phase 4
39 Carboxymethylcellulose Sodium Phase 4
40 Plasma Substitutes Phase 4
41 Blood Substitutes Phase 4
42 Neurotransmitter Agents Phase 4
43 Anticoagulants Phase 4
44 Dextrans Phase 4
45 Antipruritics Phase 4
46 Guar Phase 4
47 Flax Phase 4
48 Cyclooxygenase Inhibitors Phase 4
49 Ketorolac Tromethamine Phase 4
50 Renal Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 651)
# Name Status NCT ID Phase Drugs
1 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
2 Eight Week Feasibility Study Enrolling Dry Eye Subjects Confirmed by Four of Seven Dianostic Markers Responding to Nutritional Therapy Unknown status NCT01561040 Phase 4
3 A Randomized Masked Evaluation of Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
4 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
5 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4 Artificial tears
6 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
7 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity in Dry Eye Disease (DED) With Meibomian Gland Dysfunction (MGD). Unknown status NCT02992535 Phase 4
8 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
9 A Single-Center Evaluation of Retaine™ Ophthalmic Emulsion in the Management of Tear Film Stability and Ocular Surface Staining in Patients Diagnosed With Dry Eye Completed NCT02139033 Phase 4 Retaine™
10 Evaluation of the Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
11 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
12 Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Completed NCT02758327 Phase 4 TheraTears Lubricating Eye Drops
13 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
14 Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02986750 Phase 4
15 Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome Completed NCT01864330 Phase 4
16 Evaluation of the Effect of Repeated Usage of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
17 The Comparison of 50 % Concentration Autologous Serum Eye Drops Versus Preservative Free Artificial Eye Drop Plus 0.05 % Cyclosporin Ophthalmic Emulsion in the Treatment of Severe Dry Eye Syndrome: A Randomized Comparative Study Completed NCT03666884 Phase 4 COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1
18 A Randomized, Single-Center, Comparative Study of Rohto Dry-Aid® and Systane® Ultra in the Management of Tear Film Stability and Visual Function in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
19 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
20 The Effect of Kynex Versus Refresh Plus in Subjects With Mild to Moderate Dry Eye - A Parallel Group, Randomized, Masked Study Completed NCT00809198 Phase 4
21 Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects Completed NCT01086774 Phase 4
22 A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye Completed NCT00399230 Phase 4 Optive
23 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
24 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4 A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®;Sodium hyaluronate
25 Efficacy of Topical Cyclosporine Ophthalmic Emulsion for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
26 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
27 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
28 Bromfenac 0.09% vs. Ketorolac 0.4% During the Induction Phase of Treatment With Topical Cyclosporine for Chronic Dry Eye Patients Completed NCT00520260 Phase 4 bromfenac;ketorolac
29 Evaluation of the Repeated Usage of Systane Ultra Eyedrop Completed NCT01051804 Phase 4
30 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
31 Study to Evaluate the Physical Effect of SYSTANE QID in People That Have Moderate to Severe Dry Feeling Eyes Completed NCT00818909 Phase 4
32 Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Completed NCT01198782 Phase 4
33 A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms Completed NCT02028754 Phase 4 Sodium Carboxymethylcellulose;Levofloxacin;Prednisolone
34 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
35 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
36 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
37 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed NCT01682460 Phase 4 Refresh Tears Lubricant Eye Drops (Allergan)
38 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4 1. Optive
39 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
40 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis
41 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4 PEG-400 based artificial tear;Systane
42 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
43 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4 Azithromycin Ophthalmic Solution, 1%;Placebo
44 A Randomized Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4 No topical artificial tear;Blink® Tears Lubricant Eye Drops
45 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE) Completed NCT01105624 Phase 4 azithromycin ophthalmic solution, 1%;Visine® for Contacts®
46 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4 Systane Free
47 Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients Completed NCT01311609 Phase 4
48 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
49 A Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye: A Randomized Controlled Trial Completed NCT00386646 Phase 4 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
50 Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects Completed NCT01970917 Phase 4

Search NIH Clinical Center for Keratoconjunctivitis Sicca

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cod Liver Oil
hydroxyethyl cellulose
retinol acetate
retinyl palmitate
Sodium Chloride
SODIUM CHLORIDE 0.9% PROCESSING SOLN
SODIUM CHLORIDE GRANULES
Vitamin A
VITAMIN A (AS ACETATE & BETA CAROTENE)
VITAMIN A (AS PALMITATE & BETA CAROTENE)
VITAMIN A (NATURAL)
VITAMIN A PALMITATE (SOLUBILIZED)

Cochrane evidence based reviews: keratoconjunctivitis sicca

Genetic Tests for Keratoconjunctivitis Sicca

Genetic tests related to Keratoconjunctivitis Sicca:

# Genetic test Affiliating Genes
1 Keratoconjunctivitis Sicca 29

Anatomical Context for Keratoconjunctivitis Sicca

MalaCards organs/tissues related to Keratoconjunctivitis Sicca:

40
Eye, Salivary Gland, Testes, Bone, Thyroid, T Cells, B Cells

Publications for Keratoconjunctivitis Sicca

Articles related to Keratoconjunctivitis Sicca:

(show top 50) (show all 2122)
# Title Authors PMID Year
1
[A case of lymphocytic interstitial pneumonia complicated with primary Sjögren's syndrome followed by chest CT scanning for thirteen years]. 54 61
19260540 2009
2
Sjögren's syndrome-like disease of C57BL/6.NOD-Aec1 Aec2 mice: gender differences in keratoconjunctivitis sicca defined by a cross-over in the chromosome 3 Aec1 locus. 54 61
16918699 2006
3
Aquaporins and CFTR in ocular epithelial fluid transport. 54 61
16868675 2006
4
The lactoferrin tear test in the diagnosis of Sjögren's syndrome. 54 61
8908435 1996
5
Rapid assay of lactoferrin in keratoconjunctivitis sicca. 54 61
7842709 1994
6
Ocular surface damage and tear lactoferrin in dry eye syndrome. 54 61
7825407 1994
7
The diagnostic power of the tests for tear gland related keratoconjunctivitis sicca. 54 61
1603200 1992
8
The association between vitamin deficiency and otolaryngologic diseases: A therapeutic target. 61
31733530 2020
9
Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies: Erratum. 61
31714407 2020
10
Corneoconjunctival transposition for the treatment of deep stromal to full-thickness corneal defects in dogs: A multicentric retrospective study of 100 cases (2012-2018). 61
31950569 2020
11
Application of classification criteria of Sjogren syndrome in patients with sicca symptoms: Real-world experience at a medical center. 61
31303456 2020
12
Characteristics of patients with primary Sjögren's syndrome associated interstitial lung disease and relevant features of disease progression. 61
31902032 2020
13
Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study. 61
31361655 2020
14
Structurally coloured contact lens sensor for point-of-care ophthalmic health monitoring. 61
31989133 2020
15
[Side effects of keratoconjunctivitis sicca treatment]. 61
31407051 2020
16
Corneal hypoesthesia, aqueous tear deficiency, and neurotrophic keratopathy following micropulse transscleral cyclophotocoagulation in dogs. 61
31464376 2020
17
Finger-Prick Autologous Blood in the Treatment of Persistent Corneal Epithelial Defects. 61
31868852 2019
18
Total external ophthalmoplegia: First clinical manifestation of Sjögren's syndrome. 61
31490084 2019
19
Systematic review of oral and craniofacial findings in patients with Fabry disease or Pompe disease. 61
31405600 2019
20
Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. 61
31762357 2019
21
Assessment of meibomian gland morphology by noncontact infrared meibography in Shih Tzu dogs with or without keratoconjunctivitis sicca. 61
30715776 2019
22
Disability Related to Chronic Graft-versus-Host Disease. 61
31669175 2019
23
Clinical findings of traumatic proptosis in small-breed dogs and complications associated with globe replacement surgery. 61
31998615 2019
24
Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies. 61
31306284 2019
25
Lipemic uveitis and its etiologies in dogs: 75 cases. 61
30716194 2019
26
Mesenchymal Stem Cells Extract (MSCsE)-Based Therapy Alleviates Xerostomia and Keratoconjunctivitis Sicca in Sjogren's Syndrome-Like Disease. 61
31557796 2019
27
Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical Trials. 61
31373837 2019
28
Comparative efficacy of topical oclacitinib 0.1% and tacrolimus 0.01% in canine keratoconjunctivitis sicca. 61
30724448 2019
29
Bilateral facial paralysis as a rare neurological manifestation of primary Sjögren's syndrome: case-based review. 61
31175417 2019
30
VEMPs and Dysautonomia Assessment in Definite Cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome (CANVAS): a Case Series Study. 61
31414248 2019
31
Chronic eyelid edema and xerophthalmia secondary to periorbital hyaluronic acid filler injection. 61
31441981 2019
32
Association of Sjögren's syndrome with myotonic dystrophy type 1. 61
31466972 2019
33
Successful treatment with rituximab of IgG4-related disease coexisting with adult-onset asthma and periocular xanthogranuloma. 61
31392499 2019
34
Reduction in the inflammatory markers CD4, IL-1, IL-6 and TNFα in dogs with keratoconjunctivitis sicca treated topically with mesenchymal stem cells. 61
31430719 2019
35
Reproducibility of Ocular Surface Staining in the Assessment of Sjögren Syndrome-Related Keratoconjunctivitis Sicca: Implications on Disease Classification. 61
31453437 2019
36
MicroPulse™ transscleral cyclophotocoagulation in the treatment of canine glaucoma: Preliminary results (12 dogs). 61
30109763 2019
37
Overexpression of Smac is associated with the development of primary Sjogren's syndrome. 61
31274785 2019
38
Overexpression of Smac is associated with the development of primary Sjogren's syndrome. 61
31305346 2019
39
Clinical factors associated with worse quality-of-life scores in United States thyroid cancer survivors. 61
30898373 2019
40
Case Report: Vitamin A Deficiency and Nyctalopia in a Patient with Chronic Pancreatitis. 61
31107845 2019
41
Improving the diagnosis of canine keratoconjunctivitis sicca. 61
31154371 2019
42
The Effect of Periocular Fatty Acids and 0.15% Hyaluronate Eye Drops Application on Keratoconjunctivitis Sicca in Dogs: An Exploratory Study. 61
31122683 2019
43
Characterisation of corneal impression cytology in dogs and its application in the diagnosis of keratoconjunctivitis sicca. 61
31019006 2019
44
Mesenchymal Stem Cell Therapy in Submandibular Salivary Gland Allotransplantation: Experimental Study. 61
30801515 2019
45
[Role and mechanism of muscarinic acetylcholine receptor in the regulation of submandibular gland secretion]. 61
31209407 2019
46
A Meta-Analysis of Treatment for Primary Sjögren's Syndrome. 61
31058469 2019
47
Present and novel biologic drugs in primary Sjögren's syndrome. 61
31025931 2019
48
The impact of ocular manifestations of rheumatoid arthritis on the health-related quality of life and the functional ability of black Africans. 61
29564803 2019
49
Phenotypic features and predictors of the clinical severity of keratoconjunctivitis sicca and salivary gland dysfunction in patients with Sjögren's syndrome: a longitudinal analysis of the Korean Initiative of primary Sjögren's Syndrome (KISS) cohort. 61
30475093 2019
50
Retrospective analysis of ocular neuropathies in diabetic dogs following cataract surgery. 61
30095212 2019

Variations for Keratoconjunctivitis Sicca

Expression for Keratoconjunctivitis Sicca

Search GEO for disease gene expression data for Keratoconjunctivitis Sicca.

Pathways for Keratoconjunctivitis Sicca

GO Terms for Keratoconjunctivitis Sicca

Cellular components related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 NGF MUC5AC LTF IL4 IL1A HSPG2
2 extracellular region GO:0005576 9.65 NRTN NGF MUC5AC LTF IL4 IL1A
3 basal plasma membrane GO:0009925 8.8 ERBB3 ERBB2 AQP5

Biological processes related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.65 NGF IL4 IL1A ERBB3 ERBB2
2 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.37 IL1A CD4
3 positive regulation of viral entry into host cell GO:0046598 9.32 TRIM21 CD4
4 enzyme linked receptor protein signaling pathway GO:0007167 9.16 ERBB2 CD4
5 peripheral nervous system development GO:0007422 9.13 NGF ERBB3 ERBB2
6 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.02 NRTN NGF ERBB3 ERBB2 CD4

Molecular functions related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 8.92 ERBB3 ERBB2 CD79A CD4

Sources for Keratoconjunctivitis Sicca

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....